{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:21:51Z","timestamp":1787026911605,"version":"build-2736575974"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00055","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T23:12:52Z","timestamp":1549494772000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Bevacizumab Combined With Oxaliplatin\/Capecitabine in Patient With Refractory and Recurrent Mucinous Adenocarcinoma of the Appendix: A Case Report"],"prefix":"10.3389","volume":"9","author":[{"given":"Wenzhi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanyu","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/gut.4.2.158","article-title":"The management of primary adenocarcinoma of the vermiform appendix","volume":"4","author":"Hesketh","year":"1963","journal-title":"Gut"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1245\/s10434-012-2238-1","article-title":"Importance of histologic subtype in the staging of appendiceal tumors","volume":"19","author":"Turaga","year":"2012","journal-title":"Ann Surg Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF02236899","article-title":"Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies","volume":"41","author":"Connor","year":"1998","journal-title":"Dis Colon Rectum"},{"key":"B4","doi-asserted-by":"publisher","first-page":"728579","DOI":"10.5402\/2011\/728579","article-title":"Cancers of the appendix: review of the literatures","volume":"2011","author":"Ruoff","year":"2011","journal-title":"ISRN Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1634\/theoncologist.2010-0052","article-title":"Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy","volume":"15","author":"Winder","year":"2010","journal-title":"Oncologist"},{"key":"B6","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1634\/theoncologist.2014-0106","article-title":"FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma","volume":"19","author":"Pietrantonio","year":"2014","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12876-015-0266-6","article-title":"Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view","volume":"15","author":"Bencsikova","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1634\/theoncologist.5-suppl_1-11","article-title":"Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications","volume":"5","author":"Ellis","year":"2000","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1245\/s10434-014-4335-9","article-title":"Improved survival with anti-VEGF therapy in the treatment of unresectable appendiceal epithelial neoplasms","volume":"22","author":"Choe","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijso.2016.06.003","article-title":"Primary adenocarcinoma of the appendix: experience at La Paz University Hospital of Madrid (1967-2014)","volume":"4","author":"Arellano","year":"2016","journal-title":"Int J Surg Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/0008-5472.CAN-14-2240","article-title":"Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes","volume":"75","author":"Linnekamp","year":"2015","journal-title":"Cancer Res."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00055\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T23:12:52Z","timestamp":1549494772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00055\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":13,"alternative-id":["10.3389\/fonc.2019.00055"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00055","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,7]]},"article-number":"55"}}